LM11A-31
Tier C — Watch / tradeLM11A-31
Targets：p75NTR
Indications (approved)：进行性核上性麻痹, Alzheimer's disease
Regional status
Synthetic routes & intermediates1 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| LM11A-31 | 289475-77-0 | 2-amino-3-methyl-N-(2-morpholinoethyl)pentanamide |
| LM11A-31-001 | 2038-03-1 | 2-morpholinoethan-1-amine |
| LM11A-31-002 | 2390474-63-0 | 2-((tert-butoxycarbonyl)amino)-3-methylpentanoic acid |
| LM11A-31-003 | 1214659-50-3 | tert-butyl (3-methyl-1-((2-morpholinoethyl)amino)-1-oxopentan-2-yl)carbamate |
Frequently asked questions
What are the approved indications of LM11A-31?
Approved indications include: 进行性核上性麻痹, Alzheimer's disease.
When does the LM11A-31 patent expire?
No public expiry year is available for LM11A-31 yet; this page updates once verified.
How many synthesis routes are recorded for LM11A-31?
1 synthesis routes are recorded; the shortest is 2 steps with / total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy LM11A-31 intermediates?
All intermediates in LM11A-31 routes have CAS profiles — you can submit an RFQ per CAS and it enters the Unibest matching pool.
How do I get a quote for LM11A-31 intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-10-09